
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k090844
B. Purpose for Submission:
Modification to previously cleared assay
C. Measurand:
Norbuprenorphine (buprenorphine metabolite)
D. Type of Test:
Homogeneous enzyme immunoassay â€“ qualitative and semi- quantitative
E. Applicant:
Lin-Zhi International, Inc.
F. Proprietary and Established Names:
Buprenorphine Enzyme Immunoassay, Norpbuprenorphine Drugs of Abuse Controls,
Norbuprenorphine Drugs of Abuse Calibrators.
G. Regulatory Information:
Regulation
Product Code Classification Panel
Section
DJG Class II 21 CFR 862.3650- 91-Toxicology
Opiate Test
System
DLJ Class II 21 CFR 862.3200 91-Toxicology
Clinical
Toxicology
Calibrators
LAS Class I, 21 CFR 862.3280 91-Toxicology
reserved Clinical
Toxicology
control material
1

[Table 1 on page 1]
Product Code	Classification		Regulation		Panel
			Section		
DJG	Class II	21 CFR 862.3650-
Opiate Test
System			91-Toxicology
DLJ	Class II	21 CFR 862.3200
Clinical
Toxicology
Calibrators			91-Toxicology
LAS	Class I,
reserved	21 CFR 862.3280
Clinical
Toxicology
control material			91-Toxicology

--- Page 2 ---
H. Intended Use:
1. Intended use(s):
See Indications for use, below.
2. Indication(s) for use:
The Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay is
intended for the qualitative and semiquantitative determination of
norbuprenorphine (buprenorphine metabolite) in human urine, at cutoff
values of 5 ng/mL and 10 ng/mL. The assay is designed for prescription
use with a number of automated clinical chemistry analyzers.
The Norbuprenorphine Drugs of Abuse (DAU) Calibrators are for use as
calibrators in qualitative and semi-quantitative calibration of the Lin-Zhi
International (LZI) Buprenorphine Enzyme Immunoassay.
The Norbuprenorphine Drugs of Abuse (DAU) Controls are for use as
assayed quality control materials to monitor the precision of the Lin-Zhi
International (LZI) Buprenorphine Enzyme Immunoassay.
The assay provides only a preliminary analytical test result. A more
specific alternative chemical method must be used to obtain a
confirmed analytical result. Gas chromatography /mass spectrometry
(GC/MS) or LCMS are the preferred confirmatory methods. Clinical
consideration and professional judgment should be applied to any
drug of abuse test result, particularly when the preliminary result is
positive.
3. Special conditions for use statement(s):
The assay is for prescription use.
4. Special instrument requirements:
Automated clinical chemistry analyzers. (Performance in the studies submitted in
the 510(k) are based on the Hitachi 717.)
I. Device Description:
The assay consists of ready-to-use liquid reagents. Reagent 1 contains mouse monoclonal
anti-buprenorphine antibody, glucose-6-phosphate (G6P), nicotinamide adenine
dinucleotide (NAD) and stabilizers. Reagent 2 contains buprenorphine labeled glucose-6-
2

--- Page 3 ---
phosphate dehydrogenase (G6PDH) in buffer. The calibrators and controls are ready to
use human urine-based liquid and are sold separately.
J. Substantial Equivalence Information:
1. Predicate device name(s): LZI Buprenorphine Enzyme Immunoassay
2. Predicate 510(k) number(s): k081008
3. Comparison with predicate: The cutoffs for the new device are 5 and 10 ng/mL;
the predicate device has one cutoff at 10 ng/mL. Related to this additional lower
cutoff, there is an extra level of control material, and a change in one of the
calibrator concentrations levels. Specifically, the new device has a high calibrator
concentration of 75 ng/mL; the predicate device had a high calibrator
concentration of 100 ng/mL.
K. Standard/Guidance Document Referenced (if applicable):
None referenced.
L. Test Principle:
The Lin-Zhi Buprenorphine assay is a homogeneous enzyme immunoassay with ready-
to-use liquid reagent. The assay is based on competition between drug in the sample and
drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed
amount of antibody in the reagent. In the absence of drug in the sample, the antibody
binds the conjugated buprenorphine-labeled G6PDH thus the enzyme activity is
inhibited. When free drug is present on the sample, the antibody will bind to the free drug
and the unbound buprenorphine-labeled G6PDH exhibits its maximal enzyme activity.
The G6PDH activity is measured spectrophotometrically at 340 nm because of
conversion of NAD to NADH.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
Performance was evaluated on the Hitachi 717 Instrument.
a. Precision/Reproducibility:
Spiked samples of norbuprenorphine were prepared in a urine matrix at the
concentrations shown in the table below, and were measured, 2 runs per day, with
2 replicates per run, for 22 days. Results are tabulated below.
3

--- Page 4 ---
Total Precision for qualitative mode
Sample
Results for 5 ng/mL Results for 10 ng/mL
concentration N
cutoff cutoff
(ng/mL)
0 (negative) 88 88 negative 88 negative
2.5 (-75% c/o) 88 88 negative 88 negative
5.0 (-50% c/o) 88 43 positive, 45 negative 88 negative
7.5 (-25% c/o) 88 88 positive 88 negative
10 (cutoff) 88 88 positive 59 positive, 29 negative
12.5 (+25% c/o) 88 88 positive 88 positive
15.0 (+50% c/o) 88 88 positive 88 positive
17.5 (+50% c/o) 88 88 positive 88 positive
20 (+100% c/o) 88 88 positive 88 positive
Total Precision for semi-quantitative mode
Sample Results for Results for
concentration Mean SD Percent 5 ng/mL 10 ng/mL
(ng/mL) (ng/mL) (ng/mL) CV cutoff cutoff
0 (negative) 0.54 0.6 121% 88 negative 88 negative
2.5 (-75% c/o) 3.05 0.4 14.4% 88 negative 88 negative
62 positive,
5.0 (-50% c/o) 5.21 0.5 9.4% 28 negative 88 negative
7.5 (-25% c/o) 7.69 0.5 6.0% 88 positive 88 negative
88 positive 47 positive,
10 (cutoff) 10.03 0.5 5.3% 41 negative
12.5 (+25% c/o) 12.07 0.5 4.4% 88 positive 88 positive
15.0 (+50% c/o) 14.49 0.8 5.5% 88 positive 88 positive
17.5 (+50% c/o) 17.02 0.6 3.7% 88 positive 88 positive
20 (+100% c/o) 19.85 0.8 4.0% 88 positive 88 positive
b. Linearity/assay reportable range:
To demonstrate linearity in the semiquantitative mode, which is used for purposes
of sample dilution and quality control procedures, a drug-free urine pool spiked
with 100 ng/mL pure norbuprenorphine was serially diluted in increments of 10%
and results were obtained. For each sample the average of ten replicates was
calculated. Percent recovery ranged from 94 to 115%.
4

[Table 1 on page 4]
Sample
concentration
(ng/mL)	N	Results for 5 ng/mL
cutoff	Results for 10 ng/mL
cutoff
			
0 (negative)	88	88 negative	88 negative
2.5 (-75% c/o)	88	88 negative	88 negative
5.0 (-50% c/o)	88	43 positive, 45 negative	88 negative
7.5 (-25% c/o)	88	88 positive	88 negative
10 (cutoff)	88	88 positive	59 positive, 29 negative
12.5 (+25% c/o)	88	88 positive	88 positive
15.0 (+50% c/o)	88	88 positive	88 positive
17.5 (+50% c/o)	88	88 positive	88 positive
20 (+100% c/o)	88	88 positive	88 positive

[Table 2 on page 4]
Sample
concentration
(ng/mL)	Mean
(ng/mL)	SD
(ng/mL)	Percent
CV	Results for
5 ng/mL
cutoff	Results for
10 ng/mL
cutoff
					
0 (negative)	0.54	0.6	121%	88 negative	88 negative
2.5 (-75% c/o)	3.05	0.4	14.4%	88 negative	88 negative
5.0 (-50% c/o)	5.21	0.5	9.4%	62 positive,
28 negative	88 negative
7.5 (-25% c/o)	7.69	0.5	6.0%	88 positive	88 negative
10 (cutoff)	10.03	0.5	5.3%	88 positive	47 positive,
41 negative
12.5 (+25% c/o)	12.07	0.5	4.4%	88 positive	88 positive
15.0 (+50% c/o)	14.49	0.8	5.5%	88 positive	88 positive
17.5 (+50% c/o)	17.02	0.6	3.7%	88 positive	88 positive
20 (+100% c/o)	19.85	0.8	4.0%	88 positive	88 positive

--- Page 5 ---
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Calibrators are the same as those reviewed in k081008, except for changes in
calibrator levels. Stability and value assignment also followed the same protocols
reviewed in k081008. The value assignment procedures and results for the
additional calibrator levels in this submission were reviewed and found to be
acceptable.
d. Detection limit:
Replicates of the zero calibrator and two low-concentration spiked samples (with
concentrations between the zero-calibrator and the 5 ng/mL cutoff) were
measured to determine the lowest value that can be differentiated from the zero
calibrator with 95% confidence. In qualitative mode, the detection limit
calculated was 415 mA/min. The results from testing in semi-quantitative mode,
were reviewed to confirm that the detection limit is less than the claimed lower
cutoff of 5 ng/mL buprenorphine.
e. Analytical specificity:
Various potentially interfering substances were evaluated for positive and
negative interference with the assay. Test compounds were spiked into a
buprenorphine-free sample, as well as samples containing buprenorphine at 3, 7,
and 13 ng/mL (i.e., +/-2 ng/mL, or +/- 30% surrounding the assay cutoff
concentrations). These compounds did not affect positivity or negativity of the
samples tested. Similar results were obtained in both qualitative and semi-
quantitative modes. The potential interferents and the concentrations at which
they were tested are shown below.
Substance tested Concentration (mg/dL)
Acetone 1000
Ascorbic Acid 400
Creatinine 500
Galactose 10
r-Globulin 500
Glucose 1500
Hemoglobin 300
NaCl 6000
Oxalic Acid 100
Human Serum
500
Albumin (HSA)
Urea 2000
Ethanol 1000
pH 3 n/a
pH 11 n/a
5

--- Page 6 ---
In addition, variations in specific gravity between 1.001 and 1.027 had no effect
on results.
Cross-reactivity was evaluated by spiking concentrations up to 100,000 ng/mL of
buprenorphine metabolites into drug-free urine. Results are shown below.
Compound % Cross-reactivity
Buprenorphine 101%
Buprenorphine- 0.13%
Glucuronide
Norbuprenorphine- 0.9%
glucuronide
The package insert includes the complete list of all structurally related and
commonly co-administered drugs tested. Very small amounts of cross-reactivity
(<0.1%) were observed for heroin, levorphanol and EMDP (2-ethyl-5-methyl-3,3-
diphenylpyrroline). Cross-reactivity for other compounds tested was not detected
(<.002%). The package insert notes that there is a possibility that metabolites of
structurally-related drugs may interfere with the test and cause false results.
f. Assay cut-off:
See Detection Limit Section, above.
2. Comparison studies:
a. Method comparison with predicate device:
A total of ninety unaltered clinical samples were tested with the LZI
Buprenorphine Assay. Fifteen of the samples were from drug-free donors. Based
on GC/MS, six samples ranged from 0.1 to 2.4 ng/mL; fourteen samples ranged
from 2.5 to 4.9 ng/mL; seven samples ranged from 5 to 7.5 ng/mL and forty seven
samples were above 7.5 ng/mL. Results are shown in the tables below for both
the 5 ng/mL cutoff mode and the 10 ng/mL cutoff mode.
Low Near Cutoff Near Cutoff High Percent
Negative by Negative Positive Positive Agreement
GC/MS (concentration (concentration (concentration with GCMS
(concentration between 50% between 50% > 50% above
< 50% below below the above the the cutoff
GCMS (cid:198) the cutoff cutoff and the cutoff and the concentration))
concentration) cutoff cutoff
concentration) concentration)
5 ng/mL cutoff
BUP Assay (cid:200)
Positive 0 2 7 47 96.40%
Negative 22 12 0 0 100%
6

[Table 1 on page 6]
Compound	% Cross-reactivity
Buprenorphine	101%
Buprenorphine-
Glucuronide	0.13%
Norbuprenorphine-
glucuronide	0.9%

[Table 2 on page 6]
GCMS (cid:198)	Low
Negative by
GC/MS
(concentration
< 50% below
the cutoff
concentration)	Near Cutoff
Negative
(concentration
between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(concentration
between 50%
above the
cutoff and the
cutoff
concentration)	High
Positive
(concentration
> 50% above
the cutoff
concentration))	Percent
Agreement
with GCMS
5 ng/mL cutoff
BUP Assay (cid:200)					
Positive	0	2	7	47	96.40%
Negative	22	12	0	0	100%

--- Page 7 ---
Low Near Cutoff Near Cutoff High Percent
Negative by Negative Positive Positive Agreement
GC/MS (concentration (concentration (concentration with GCMS
(concentration between 50% between 50% > 50% above
< 50% below below the above the the cutoff
GCMS (cid:198) the cutoff cutoff and the cutoff and the concentration))
concentration) cutoff cutoff
10 ng/mL
concentration) concentration)
cutoff
BUP Assay (cid:200)
Positive 0 2 8 31 95.1%
Negative 36 12 1 0 98.0%
The tables above show that in this study qualitatively discrepant results were observed
only for near-cutoff samples (+/- 50% of the cutoff concentration.)
b. Matrix comparison: Not applicable. The test is only for urine specimens.
3. Clinical studies:
a. Clinical Sensitivity: Not reviewed for this device type.
b. Clinical specificity: Not reviewed for this device type.
c. Other clinical supportive data (when a. and b. are not applicable):
4. Clinical cut-off:
Not applicable; the device is for determining presumptive positive or negative
based on the analytical cutoffs of 5 ng/mL and 10 ng/mL.
5. Expected values/Reference range:
Not applicable. The test is not intended for quantifying buprenorphine or
norbuprenorphine; the semi-quantitative mode is for purposes of (1) enabling
laboratories to determine an appropriate dilution of the specimen for confirmation
by a confirmatory method such as GCMS and (2) permitting laboratories to
establish quality control procedures.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
7

[Table 1 on page 7]
GCMS (cid:198)	Low
Negative by
GC/MS
(concentration
< 50% below
the cutoff
concentration)	Near Cutoff
Negative
(concentration
between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(concentration
between 50%
above the
cutoff and the
cutoff
concentration)	High
Positive
(concentration
> 50% above
the cutoff
concentration))	Percent
Agreement
with GCMS
10 ng/mL
cutoff
BUP Assay (cid:200)					
Positive	0	2	8	31	95.1%
Negative	36	12	1	0	98.0%

--- Page 8 ---
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
8